ARS Pharmaceuticals, Inc.
SPRY
$15.39
$0.996.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 97.12M | 89.15M | 2.57M | 500.00K | 10.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 97.12M | 89.15M | 2.57M | 500.00K | 10.00K |
| Cost of Revenue | 19.27M | 20.46M | 19.97M | 18.44M | 18.85M |
| Gross Profit | 77.85M | 68.69M | -17.40M | -17.94M | -18.84M |
| SG&A Expenses | 104.92M | 71.78M | 43.11M | 38.80M | 43.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 124.19M | 92.23M | 63.07M | 57.24M | 62.01M |
| Operating Income | -27.07M | -3.08M | -60.51M | -56.74M | -62.00M |
| Income Before Tax | -15.36M | 8.29M | -49.10M | -44.84M | -49.70M |
| Income Tax Expenses | 288.00K | 288.00K | -- | -- | -- |
| Earnings from Continuing Operations | -15.65 | 8.00 | -49.10 | -44.84 | -49.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.65M | 8.00M | -49.10M | -44.84M | -49.70M |
| EBIT | -27.07M | -3.08M | -60.51M | -56.74M | -62.00M |
| EBITDA | -26.72M | -3.00M | -60.44M | -56.67M | -61.94M |
| EPS Basic | -0.16 | 0.08 | -0.51 | -0.47 | -0.52 |
| Normalized Basic EPS | -0.12 | 0.03 | -0.34 | -0.32 | -0.35 |
| EPS Diluted | -0.25 | -0.01 | -0.51 | -0.47 | -0.52 |
| Normalized Diluted EPS | -0.18 | -0.03 | -0.34 | -0.32 | -0.35 |
| Average Basic Shares Outstanding | 389.32M | 387.74M | 386.48M | 385.02M | 383.11M |
| Average Diluted Shares Outstanding | 411.14M | 409.56M | 386.48M | 385.02M | 383.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |